Tous Actualités
Suivre
Abonner AGENNIX AG

AGENNIX AG

EANS-News: AGENNIX AG /dievini Hopp BioTech Holding and Related Persons and Entities Granted Exemption from Mandatory Tender Offer for Agennix AG

Planegg/Munich (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information
Planegg/Munich (Germany), November 4,
2010 - Agennix AG (Frankfurt Stock Exchange (Prime Standard): 
AGX/ISIN DE000A1A6XX4) was informed yesterday that the German Federal
Financial Supervisory Authority (Bundesanstalt fuer 
Finanzdienstleistungsaufsicht) (BaFin) has yesterday granted the 
Company´s largest shareholder, dievini Hopp BioTech holding GmbH & 
Co. KG ("dievini"), and certain other persons and legal entities to 
whom dievini´s share ownership is attributed, an exemption from the 
obligations pursuant to Section 35 of the German Takeover Act to 
publish the acquisition of control, to provide BaFin an offer 
document, and to publish a mandatory tender offer to the other 
shareholders of Agennix AG in connection with the capital increase of
the Company completed in October 2010.
As a result of their participation in the capital increase completed 
on October 4, 2010, dievini and certain other persons and legal 
entities to whom dievini´s share ownership is attributed, acquired 
control of the Company in the meaning of Section 29 (2) of the German
Takeover Act and would have been required to make a mandatory tender 
offer to the other shareholders of Agennix had the exemption not been
granted.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is 
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company´s most
advanced program is talactoferrin, an oral therapy that has 
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe 
sepsis. Talactoferrin is currently in Phase III clinical trials in 
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical 
development programs include RGB-286638, a multi-targeted kinase 
inhibitor in Phase I testing, and a topical gel form of talactoferrin
for diabetic foot ulcers. Agennix´s registered seat is in Heidelberg,
Germany. The Company has three sites of operation: Planegg/Munich, 
Germany; Princeton, New Jersey and Houston, Texas. For additional 
information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to 
risks and uncertainties, many of which are beyond our control, that 
could cause future results, performance or achievements to differ 
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could 
differ materially depending on a number of factors, and we caution 
investors not to place undue reliance on the forward-looking 
statements contained in this press release. Forward-looking 
statements speak only as of the date on which they are made and 
Agennix undertakes no obligation to update these forward-looking 
statements, even if new information becomes available in the future.
end of announcement                               euro adhoc

Further inquiry note:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: AGENNIX AG
Plus de actualités: AGENNIX AG